Motorola Solutions Delivers Unrivalled Versatility for Frontline Workers
27.10.2020 16:00:00 EET | Business Wire | Press release
A global pandemic, ever-increasing volumes of data to manage and greater demand to do more with limited resources - the world has never been more complex for public safety agencies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005282/en/
Motorola Solutions' next-generation Terrestrial Trunked Radio (TETRA) device: the MXP600 (Photo: Business Wire)
Siloed systems and devices that don’t talk with each other can add to an already existing complexity. First responders need mission-critical technology that offers an intuitive and smart experience to respond effectively in the “heat of the moment,” as well as flexible tools that enable them to connect seamlessly with a broader ecosystem of technologies.
Motorola Solutions is launching its next-generation Terrestrial Trunked Radio (TETRA) device: the smart and powerful MXP600, to meet the needs of public safety personnel today and well into the future. The lightweight yet highly rugged radio takes the proven capabilities of mission-critical voice communication to new levels and can collaborate with other solutions.
“Frontline professionals will always need their radio in high-stress situations to serve as their lifeline, but they also might require collaboration with other devices that they carry, including smartphones and body worn video cameras, without compromising the security or reliability of their radio voice communications,” said Mark Schmidl, senior vice president at Motorola Solutions.
“Instead of handling multiple devices simultaneously they can activate other devices through the one that feels most natural and intuitive to use in that situation. For example, if a police officer presses the emergency button in a life-threatening situation, the radio will in the future be able to automatically activate the body worn camera, without the officer needing to start the process separately. It's all about simplifying yet elevating key features of mission-critical communications,” explained Katja Millard, senior director devices at Motorola Solutions.
The introduction of the MXP600 will help agencies to flexibly evolve their mission-critical solutions while taking full advantage of the benefits of secure radio voice communications:
- Be clearly heard in the noisiest environments. The MXP600 uses intelligent microphone technology to suppress background noise and has a maximum loudness that is around four times louder than a typical smartphone. When operating in windy conditions, the device automatically uses the loudspeaker as an additional microphone for optimal wind noise mitigation. When multiple radios are in close proximity, the MXP600 automatically eliminates acoustic feedback to allow for effective communication.
- Radically accelerate device management to keep frontline workers in the field. Over-The-Air-Programming (OTAP) makes it possible for radios to be updated on-the-go and within minutes, avoiding the time, logistics and costs involved with traditional radio programming. OTAP is fast, secure and convenient to maximize the productivity of frontline workers and help to keep them in the field.
- Flexible collaboration. Use your radio in the way that suits you best, with a smartphone app for scrolling through talkgroups, sending secure messages and discreet radio communication when you need it. The new M-RadioControl app offers a flexible way for smartphones to work alongside the MXP600. The NFC chip embedded in the MXP600 makes pairing quick and easy, while Bluetooth 5.0 means the wireless connection between radio, smartphone and other devices remains secure.
The MXP600 integrates the technologies emergency services rely upon to focus on their mission to keep the community safe.
Videos
Adaptive Mission-Critical Audio
Designed and Tested for Extreme Conditions
Frontline Safety Today And Tomorrow
Access a media kit with videos and images here.
About Motorola Solutions
Motorola Solutions is a global leader in mission-critical communications and analytics. Our technology platforms in mission-critical communications, command centre software, video security & analytics, bolstered by managed & support services, make communities safer and help businesses stay productive and secure. At Motorola Solutions, we are ushering in a new era in public safety and security. Learn more at www.motorolasolutions.com.
Follow @MotoSolutions on Twitter
Follow @MotorolaSolutions on Instagram
Follow @MotorolaSolutions on LinkedIn
Like @MotorolaSolutions on Facebook
MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license. All other trademarks are the property of their respective owners. ©2020 Motorola Solutions, Inc. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005282/en/
Contact information
Elvan Lindberg
Motorola Solutions
Mobile: +46 (0)707448893
Elvan.Lindberg@motorolasolutions.com
Susanne Stier
Motorola Solutions
Mobile: +49 (0)172 6161773
Susanne.Stier@motorolasolutions.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
